MET and colorectal carcinoma: AMG 337, an oral ATP-competitive TKI specific to MET, caused a strong response in patients with MET-amplified upper gastrointestinal tract cancer in phase I and II trials.325,326 Savolitinib, a selective MET inhibitor, displayed marked antitumour potential under experimental conditions and appeared to be effective against renal cell cancer327,328 and is being investigated in a metastatic CRC phase I trial.